Milestone Pharmaceuticals Inc.

Contributing Author

Recent Articles by Milestone Pharmaceuticals Inc.

Nov-12	Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update MIST GlobeNewswire
Nov-04	Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MIST GlobeNewswire
Nov-03	Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025 MIST GlobeNewswire
Oct-09	Milestone Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025 MIST GlobeNewswire
Aug-19	Milestone Pharmaceuticals to Present at Upcoming Conferences MIST GlobeNewswire
Aug-12	Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update MIST GlobeNewswire
Jul-11	Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants MIST GlobeNewswire
Jul-11	Milestone Pharmaceuticals Announces Proposed Public Offering MIST GlobeNewswire
Jul-11	Milestone Pharmaceuticals Announces FDA Acceptance of the Company's Response to the CRL for CARDAMYST (etripamil) Nasal Spray MIST GlobeNewswire
Jun-16	Milestone Pharmaceuticals Submits Response to the FDA's CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting MIST GlobeNewswire
May-28	Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference MIST GlobeNewswire
May-14	Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update MIST GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.